Zurück zur Übersicht

blog

SFDR Art. 8 or Art. 9? What’s the difference?

September 14, 2021 + Jessica Di Palo
1 Minuten zu lesen

It all started on the 10th of March of this year, the day on which the ESG – Sustainable Finance Disclosure Regulation (EU) 2919/2088 came into effect. In this blog post, we will be highlighting the differences between the various classifications of assets such as Art. 6, Art. 8, and Art. 9 of the Sustainable Finance Disclosure Regulation (SFDR).

SFDR_Art_9 Art. 8

In the last decades, our world and societies have been facing various alarming environmental emergencies. Governments, Politicians, Companies, and even Celebrities are talking about a wide range of raising concerns, often under the premise: “act now!”. The establishment of the Paris Agreement was the very first step towards a universal, legally binding, global climate change agreement at the Paris climate conference in December 2015. The target? To reduce emissions. Precisely: to keep the increase in global average temperature to well below 2°C and to aim to limit the increase to a maximum of 1.5°C. The next step was to set up the 2030 Agenda for Sustainable Development. As a “plan of action for people, planet and prosperity” the agenda 2030 aims with 17 Sustainable Development Goals (SDGs) to “strengthen universal peace in larger freedom”.

ESG vs. SFDR

In the investment sector, we have been using environmental, social and governance (ESG) characteristics to evaluate potential portfolio companies to achieve the target of more sustainable investments. For the financial sector, a new regulation was put into action in 2021 – the Sustainable Finance Disclosure (SFDR). Starting from March 10th the SFDR sets out sustainability disclosure requirements for different participants of the financial market, advisers, and financial products. The regulation focuses on foreseen metrics for evaluating ESG outcomes of any given investment procedure. The goal here is to disclose, as the regulation clearly states in its name. A variety of rules are placed to make sure that any harmful impact by investee companies gets identified.

At MTIP we acted and ratified the regulations early on. Furthermore, we are fully compliant with Article 9 of the regulations. But what does this even mean? SFDR brings one important set of rules to the table, to classify mandates and funds into three distinctive categories.

SFDR Art. 6 vs. Art. 8 vs. Art. 9

We will have a closer look at Art. 6, Art.8, and Art. 9 of the regulation:

Article 6: Transparency of the integration of sustainability risks

Article 6 covers funds that do not promote themselves as being sustainable. This means that these types of funds do not integrate ESG factors and objectives into their strategy or investment process. No major changes occurred after the SFDR was established, meaning that these types of companies can continue with their business in the EU if they label themselves as non-sustainable. Given that SFDR regulations are getting more and more attention from institutional investors, these types of funds will certainly face difficult times in marketing their funds in the future.

Article 8: Transparency of the promotion of environmental or social characteristics in pre-contractual disclosures

Article 8 Funds are referred to as “Light Green Funds” and must meet the two following requirements:

  1. These funds need to promote social or environmental characteristics among other factors during investment processes. Used indicators to assess such undertakings need to be disclosed.
  2. Investee companies should follow good governance practices regarding management structures, employees, renumeration of staff and tax compliance. Therefore, a policy on good governance should be established by the Fund Manager and disclosed to the public.

Article 9: Transparency of sustainable investments in pre-contractual disclosures

Finally, SFDR Article 9 defines “Dark Green Funds”. We focus here on the product itself, namely the fund. Let’s take a closer look at the article. There are three distinctions of dark green funds, as we can see in the regulation.

  1. Where a financial product has sustainable investment as its objective and an index has been designated as a reference benchmark, the information to be disclosed pursuant to Article 6(1) and (3) shall be accompanied by the following:

(a) information on how the designated index is aligned with that objective;

(b) an explanation as to why and how the designated index aligned with that objective differs from a broad market index.

  1. Where a financial product has sustainable investment as its objective and no index has been designated as a reference benchmark, the information to be disclosed pursuant to Article 6(1) and (3) shall include an explanation on how that objective is to be attained.
  2. Where a financial product has a reduction in carbon emissions as its objective, the information to be disclosed pursuant to Article 6(1) and (3) shall include the objective of low carbon emission exposure in view of achieving the long‐term global warming objectives of the Paris Agreement.

 

The first two (1 + 2) set out that the fund itself has sustainable investments as its target. The distinction between the two lies in the fact of whether there is an index that was established as a reference or not. The last one (3) focuses on the reduction of carbon emissions.

Dark green funds are currently the highest classification of sustainable investments a European fund can achieve. We are extremely proud that our MTIP Fund two is one of the first funds to get this qualification. Experts argue that most European funds might only reach the SFDR Article 8 status as a “light green fund”.

 

Are you interested to learn more about our approach? And how we did achieve the dark green status? Get in touch with us!

 

Share the Article

blog

Dealroom Report: Tooling the Physicians of the Future

European startups addressing clinical capacity bottlenecks

press

MTIP Office Featured in Swiss Office Blog

MTIP Office Featured in Swiss Office Blog

blog

Diversity, Equity, and Inclusion: The 3 Key Drivers for Success – An Interview with Caroline Noublanche

Dieser Text erscheint auf allen Übersichtsseiten (z.B. Story-Karussell)

blog

Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch

MTIP Co-Founder and Managing Partner Dr. Christoph Kausch gives insight into growth capital decisions.

news

Rahel Hafner passed the Certificate in ESG Investing by CFA Institute

Rahel Hafner Receives Certificate in ESG Investing

news

MTIP’s HealthCare Clinic 2022

This year's HealthCare Clinic was held unter the motto: „Surfing the Healthtech Waves of Change“.

blog

What Makes a Great Founder/Investor Relationship?

Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva

news

Christoph Kausch selected by Real Deals as most influential for 2022

Christoph Kausch named by Real Deals most influential for 2022

news

MTIP leads €17 million financing round in virtual fertility clinic Apricity

New MTIP investment

news

MTIP leads the €20 million growth financing round in LynxCare

Largest capital round ever in digital health in Belgium

blog

Pioneering the use of machine learning algorithms to turbo-charge drug development

Intelligencia revolutionizes drug development

blog

The psychology of decision making

What makes a good investor?

news

MTIP schliesst zweiten Healthtech Growth Fonds mit $250 Millionen

MTIP schliesst zweiten Healthtech Fund

blog

Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics

Cynerio's new product Cynerio Now!

news

MTIP invests in Mediktor

Dieser Text erscheint auf allen Übersichtsseiten (z.B. Story-Karussell)

news

MTIP invests in Mediktor

MTIP investiert in medizinischen Assistenten

blog

SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right

news

MTIP participates in Oviva’s new $80m Series C funding

MTIP invests in Oviva

news

MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia

blog

Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey

blog

Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations

news

MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II

blog

How to pitch to a healthtech Investor

Blog Pitching

}